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Summary
Introduction: Salivary duct carcinoma (SDC) is an uncommon entity of salivary gland cancers
with a poor prognosis due to local aggressiveness or distant recurrences involving lymph nodes,
lung, and long bones, in which secondary lesions are usually osteolytic. The authors report
the ﬁrst case of mandibular SDC, atypical due to its osteosclerotic presentation and its site,
attributed to aggressive neural spread of the tumor along the trigeminal nerve.
Case study: This asymptomatic osteosclerotic bone involvement was diagnosed based on patho-
logical enhancement of the trigeminal nerve demonstrated on MRI and was accompanied by
facial nerve involvement up to its third intracranial portion. Radical surgery ensured disease
control with continued good quality of life at the 4-year follow-up visit.
Conclusion: Nerve enhancement on MRI and determination of speciﬁc tumor markers (HER-
2/neu and p53) should be taken into account to evaluate the prognosis of SDC and to propose
appropriate surgical treatment.
. All© 2010 Elsevier Masson SAS∗ Corresponding author. Tel.: +33 1 40 87 55 71;
fax: +33 1 46 25 23 62.
E-mail addresses: diane.lazard@bjn.aphp.fr,
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ntroduction
alivary duct carcinoma (SDC) is an uncommon entity of sali-
ary gland cancers (1—3% of salivary gland cancers [1] and
—16% of parotid cancers [2,3]). Histologically, it is very
lose to mammary duct carcinomas, also expressing andro-
enic receptors [3]. Treatment is ﬁrst surgical, even radical
ith lymph node evidement, followed by radiotherapy [2].
served.
1 D.-S. Lazard et al.
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ts negative prognosis stems from local recurrences or sec-
ndary remote lesions, occurring in more than half of the
ases [1]. Metastases are to the lymph nodes, lungs, or long
ones, in which lesions are usually osteolytic [2].
We report herein a case of SDC, atypical in its nerve inva-
ion aggressiveness along the facial nerve up to its third
ntracranial portion and along the trigeminal nerve, leading
o osteosclerotic mandibular extension.
ase study
53-year-old female patient consulted in our unit for the
udden and initial appearance of total left-sided facial
aralysis, grade VI on the House and Brackman classiﬁcation
4]. No parotid mass was palpable and there was no notable
ifference in size compared to the contralateral gland. Two
psilateral adenopathies were noted. The otoscopy as well as
udiometry were normal. The acoustic reﬂex was preserved,
ndicating facial nerve involvement situated after the emer-
ence of the chorda tympani. Examination of the cranial
erve pairs demonstrated hypoesthesia of the left side of
he chin and teeth 31—34, corresponding to the trigemi-
al innervation areas. No pain, lingual hypoesthesia, dental
obility, or oral mucosa lesions were observed. The diag-
ostic hypothesis at this time was an intraparotid malignant
umor invading the facial nerve and the trigeminal nerve via
arapharyngeal lymph gland extension in contact with the
oramen ovale.
MRI with gadolinium injection demonstrated homoge-
ously increased volume of the left parotid gland, with
ntense contrast product uptake (Fig. 1) and pathological
psilateral adenopathies. The radiologist also noted an
bnormal signal within the left mandibular horizontal
ranch. The extracranial portion of the trigeminal nerve
igure 1 MRI (frontal plane) with gadolinium injection show-
ng homogenous enhancement of the entire left parotid gland,
ypassing the mandibular condyle and extending medially to
he foramen ovale (black arrow) and laterally to the tympanic
one (not shown). The left parotid gland measures 36.3mm in
ransverse diameter and 47.6mm in anteroposterior diameter
ersus 28.3mm and 45.1mm for the right gland, respectively.
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ligure 2 Bone window CT image in 3D reconstruction (axial
lane) of the osteosclerotic lesion of the horizontal branch of
he left mandible.
lso took up the contrast product pathologically, particularly
t its penetration into the mandible. Its intracranial por-
ion was normal, however, CT, performed to better evaluate
he left hemimandible, showed local hyperdense enlarge-
ent with periosteal appositions (Fig. 2). The workup was
ompleted with (18)F-ﬂuorodeoxyglucose positron emission
omography (PET), demonstrating substantial enhancement
standardized uptake values [SUV] >6) of the left parotid,
he mandible, and adenopathies in zone IIA. There was no
istant ﬁxation. The parotid and mandible lesions appeared
o be clearly distinct (Fig. 3).In this atypical context of synchronous osteosclerotic
andible and parotid lesions, diagnostic biopsies were done,
evealing SDC. The androgen receptors (monoclonal AR27
eceptors; ZYMED, Cergy Pontoise, France) were expressed
igure 3 (18)F-Fluorodeoxyglucose positron emission tomog-
aphy (frontal plane): pathological enhancement of the inferior
ole of the left parotid, an adenopathy in zone IIA, and the
orizontal mandibular branch. The ﬁxations of these three
esions are distinct and intense.
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Figure 5 Inﬁltrating SDC (hematoxylin-eosin-saffron [HES
staining], moderate magniﬁcation). A. Within the parotid gland:
note the cribriform ductal component and the necrosis, the
large cells with a pink cytoplasm and pleomorphic nuclei.
B. Within the mandible: carcinoma inﬁltrating bone and pro-
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eFigure 4 Dental panoramic X-ray of the horizontal branch of
the left mandible reconstructed with an osteocutaneous ﬁbular
free ﬂap.
by the tumor, but the expression of HER-2/neu and p53
(DAKO, Trappes, France) was low. Low HER-2/neu and p53
expression has been reported to be a factor of better
prognosis [1], and therefore the multidisciplinary oncology
meeting decided to propose radical surgery with ipsilat-
eral lymph node evidement. The surgery associated left
radical parotidectomy, petrosectomy, and hemimandibulec-
tomy, reconstructed with a local ﬂap from the temporal
muscle and a microanastomosed osteocutaneous ﬁbular free
ﬂap (Fig. 4).
Examination of the histological specimen conﬁrmed
parotid SDC, comprising an invasive carcinomatous prolifer-
ation made up of pseudonodular cavities ﬁlled with mucoid
material. There was considerable perineural sheath tumoral
invasion. The intramandibular lesion was histologically iden-
tical, surrounded by osteosclerosis of trabecular bone
(Fig. 5). The facial nerve was invaded up to its intramas-
toid portion; the resection was entirely in healthy tissue.
The trigeminal nerve was also involved but distant from its
emergence from the foramen ovale (where it was resected).
Lymphatic evidement included ﬁve metastatic lymph nodes
with no capsular breakage. Surgery was therefore completed
with chemoradiotherapy.
After 4 years of follow-up, the patient has presented no
local recurrence or secondary lesions, either clinically or on
complementary exams (MRI, PET).
Discussion
It seems that this case is the ﬁrst reported case of an
osteosclerotic SDC lesion in a short bone. SDCs usually affect
men older than 60 years of age [1,2] presenting a painful
parotid mass (33% of cases [2]) and facial paresis in one zone
(42—62% of cases [2,5,6]). Metastases, when they occur in
long bones, appear after a medial time of 2 years [1,2]. The
atypical clinical presentation reported herein, i.e., a pain-
less development without a distinctive mass and delayed
sudden total facial paralysis, resulted in the patient con-
sulting late. Moreover, the mandibular lesion was diagnosed
by the radiological exam given that the bone invasion had
no clinical expression and the chin and tooth hypoesthe-
sia was initially attributed to trigeminal nerve invasion by
tumor extension close to the foramen ovale (after its division
into its two terminal branches). Mandibular bone metastases
are usually osteolytic and are suspected with hypersaliva-
S
h
a
oounced osteosclerosis.
ion, pain, paresthesia, abnormal palpation, tooth mobility,
nd/or trismus at presentation [7]. In the present case, the
ifferent diagnoses for this mandibular lesion were metasta-
is, invasion from the adjacent tissues, or a secondary lesion
ith diffusion along the inferior alveolar nerve. However,
he presence of this sclerosing lesion simultaneously with
parotid tumor were not highly suggestive of metastasis
n this context [1,2,7]. In addition, the absence of an oral
ucosa lesion associated with visualization of two clearly
istinct lesions on PET, with no uptake between the two,
lso argued against the hypothesis of invasion from adjacent
issues. The mandibular lesion was therefore related to the
umor dissemination along the trigeminal nerve given the
athological enhancement on MRI and the association with
xtensive facial invasion. Even though perineural invasion of
DC is well known (80% of cases) [2,6], only a single study
as reported the case of symptomatic intracranial extension
long the trigeminal nerve [8].
The prognosis of SDC is negative, with overall survival
f 56months [1]. However, quantiﬁcation of HER-2/neu
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the jawbones: analysis of 390 cases. J Oral Pathol Med92
nd p53 tumoral markers can aid in management by pro-
iding additional prognostic indices [1]. An alternative to
urgery when this is impossible could be antiandrogenic hor-
one treatment, which has been successfully attempted
n one case [3]. This therapy requires more detailed
ssessment.
onclusion
his ﬁrst case of an osteosclerotic location of SDC illustrates
he strong neural tropism of this tumor. With an attentive
earch for pathological enhancement on MRI and quantiﬁca-
ion of survival markers, treatment adapted to the prognosis
an be proposed.
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